Breaking News, Collaborations & Alliances

Fujifilm Diosynth Biotechnologies Teams with COVID-19 Therapeutics Accelerator

To reserve manufacturing capacity and provide technical expertise to deliver future COVID-19 therapies

By: Contract Pharma

Contract Pharma Staff

Fujifilm Diosynth Biotechnologies, a biologics contract development and manufacturing organization (CDMO), has unveiled plans to reserve manufacturing capacity for a future COVID-19 therapy for the COVID-19 Therapeutics Accelerator. The Therapeutics Accelerator is an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed-up the response to the global pandemic.   Currently, there are no established therapies for the treatment of COVID-19. To help address...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters